Candel Therapeutics, Inc.

CADL Healthcare Biotechnology

Candel Therapeutics, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $125,000.00.

EPS
−477.8%
Free cash flow
−93.4%
Total debt
+525.8%

Quarter to June 2026, against a year earlier

8.66 0.62 +7.71%
Market cap
$615.2M
P/E
0.0×
Fwd P/E
−1.8×
Dividend yield
—
F-score
1/9
Altman Z
−1.20
Beneish M
n/a
Dividend safety
n/a

A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.

Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Total current assets
204.16 197.75 121.39 90.13
Total non-current assets
3.99 4.17 3.81 3.46
Total Assets
208.15 201.92 125.20 93.60
Total current liabilities
12.69 7.05 9.00 10.93
Total non-current liabilities
69.33 56.84 64.28 2.55
Total liabilities
82.02 63.89 73.27 13.47
Common Equity (Total)
126.13 138.03 51.92 80.12
Shareholders Equity (Total)
126.13 138.03 51.92 80.12
Total Debt
47.83 47.48 47.13 5.20

Show all line items

In millions of $ except per-share values · columns are period end dates